Is it safe?
Can AMRX take a bad year?
Amneal Pharmaceuticals, Inc. carries $2.37B of net debt at 4.05× EBITDA: a heavy load to carry through a bad year.
$2.37B
Net debt · as at Q1 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 4.05×
Net debt / EBITDA · 4.48× a year ago · the load is coming down
- Altman Z-score
- 2.19
Altman Z-score · grey zone, between 1.8 and 3
- Annualised volatility
- 35%
Annualised volatility · about as steady as the market itself
Details›
- Total debtQ1 2026
- $2.57B
- Cash and short-term investments
- $198M
- Net debt
- $2.37B
- EBITDA, trailing twelve months
- $587M
- Operating profit, trailing twelve months
- $436M
- Total debt / EBITDA
- 4.38×
- Annualised volatilitytwo years of daily moves
- 35%
- Worst drawdown on file
- −95%
- Below its 52-week high
- −4.6%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers - Specialty & Generic
Ranks #22 of 28 by Smart Score